X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs PANACEA BIOTECH - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD PANACEA BIOTECH WYETH LTD/
PANACEA BIOTECH
 
P/E (TTM) x 27.7 -21.8 - View Chart
P/BV x 5.3 3.1 175.2% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 WYETH LTD   PANACEA BIOTECH
EQUITY SHARE DATA
    WYETH LTD
Mar-13
PANACEA BIOTECH
Mar-14
WYETH LTD/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,044149 702.4%   
Low Rs81882 993.9%   
Sales per share (Unadj.) Rs298.684.1 354.8%  
Earnings per share (Unadj.) Rs57.2-18.3 -312.7%  
Cash flow per share (Unadj.) Rs58.4-6.7 -872.0%  
Dividends per share (Unadj.) Rs17.000-  
Dividend yield (eoy) %1.80-  
Book value per share (Unadj.) Rs249.583.7 298.0%  
Shares outstanding (eoy) m22.7261.25 37.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.11.4 227.2%   
Avg P/E ratio x16.3-6.3 -257.9%  
P/CF ratio (eoy) x15.9-17.2 -92.5%  
Price / Book Value ratio x3.71.4 270.5%  
Dividend payout %29.70-   
Avg Mkt Cap Rs m21,1577,074 299.1%   
No. of employees `0000.52.8 17.9%   
Total wages/salary Rs m4001,449 27.6%   
Avg. sales/employee Rs Th13,787.41,874.1 735.7%   
Avg. wages/employee Rs Th813.0527.0 154.3%   
Avg. net profit/employee Rs Th2,643.3-407.7 -648.3%   
INCOME DATA
Net Sales Rs m6,7835,154 131.6%  
Other income Rs m353100 353.3%   
Total revenues Rs m7,1365,254 135.8%   
Gross profit Rs m1,617-766 -211.1%  
Depreciation Rs m27711 3.7%   
Interest Rs m61,503 0.4%   
Profit before tax Rs m1,938-2,881 -67.3%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m-51,771 -0.3%   
Tax Rs m63217 3,763.1%   
Profit after tax Rs m1,301-1,121 -116.0%  
Gross profit margin %23.8-14.9 -160.3%  
Effective tax rate %32.6-0.6 -5,593.8%   
Net profit margin %19.2-21.8 -88.1%  
BALANCE SHEET DATA
Current assets Rs m6,9843,810 183.3%   
Current liabilities Rs m2,0568,365 24.6%   
Net working cap to sales %72.6-88.4 -82.2%  
Current ratio x3.40.5 745.8%  
Inventory Days Days99156 63.8%  
Debtors Days Days2467 35.6%  
Net fixed assets Rs m24414,480 1.7%   
Share capital Rs m22761 370.6%   
"Free" reserves Rs m5,441903 602.5%   
Net worth Rs m5,6685,127 110.5%   
Long term debt Rs m255,832 0.4%   
Total assets Rs m7,90119,433 40.7%  
Interest coverage x353.3-0.9 -38,551.8%   
Debt to equity ratio x01.1 0.4%  
Sales to assets ratio x0.90.3 323.7%   
Return on assets %16.52.0 841.6%  
Return on equity %22.9-21.9 -104.9%  
Return on capital %34.03.6 936.3%  
Exports to sales %0.224.5 0.9%   
Imports to sales %36.310.2 356.9%   
Exports (fob) Rs m151,264 1.2%   
Imports (cif) Rs m2,465525 469.8%   
Fx inflow Rs m151,539 1.0%   
Fx outflow Rs m2,677942 284.2%   
Net fx Rs m-2,662597 -445.7%   
CASH FLOW
From Operations Rs m923599 154.1%  
From Investments Rs m317-438 -72.4%  
From Financial Activity Rs m-481-303 159.0%  
Net Cashflow Rs m759-141 -537.2%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 0.6 1,883.3%  
FIIs % 7.2 1.3 553.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 23.6 128.8%  
Shareholders   21,978 10,259 214.2%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  TORRENT PHARMA  STRIDES SHASUN LTD  

Compare WYETH LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5%

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD 8-QTR ANALYSIS

COMPARE WYETH LTD WITH

MARKET STATS